YM BioSciences Inc. (AMEX: YMI) 20% HIGHER; announced top-line results from its randomized, placebo-controlled Phase IIb trial of AeroLEF in opioid naive patients with post-operative pain following orthopedic surgery. AeroLEF met the primary endpoint of the study, showing a statistically significant difference in SPRID4 from placebo (p=0.0194).
NVE Corp (Nasdaq: NVEC) 14% HIGHER; reports Q1 EPS of $0.33, 6 cents better than estimates.(0.27) Revenues were $4.57 million vs. $4.38 million consensus.
MINRAD International, Inc. (AMEX: BUF) 11% HIGHER; announced it has received approval from the FDA to market Sojourn inhalation anesthetic.
Sirenza Micro (Nasdaq: SMDI) 11% HIGHER; reports Q1 EPS of $0.12, 2 cents better than estimates.(0.10) Revenues were $39.1 million vs. $36.97 million consensus.
Axcelis Technologies (Nasdaq: ACLS) 10% LOWER; reports Q1 EPS of $0.03, 1 cent worse than estimates.(0.04) Revenues were $97.5 million vs. $97.04 million consensus. Sees Q2 EPS of $0.03-$0.07 versus the consensus of $0.09. Sees Q2 revs of $108-$118 million versus the consensus of $113.4 million.
JDS Uniphase (Nasdaq: JDSU) 9% LOWER; reports Q3 EPS of $0.06, 4 cents worse than estimates.(0.10) Revenues were $361.7 million vs. $346.54 million consensus. Sees Q4 revs of $325-$345M versus the consensus of $354.5M.
Smith Micro Software (Nasdaq: SMSI) 9% LOWER; reports Q1 EPS of $0.20, 3 cents better than estimates.(0.17) Revenues were $17.7 million vs. $17.52 million consensus
Andersons (Nasdaq: ANDE) 8% LOWER; reports Q1 earnings of $0.51 per share above the consensus of $0.33. Revenues came in at $409.1 million versus the consensus of $326.8 million. Sees FY07 EPS of $2.35-$2.60 versus the consensus of $2.71.
Maxwell Technologies (Nasdaq: MXWL) 8% LOWER; reports Q1 loss of $0.25, 1 cent worse than estimates.(-.24) Revenues were $12.6 million vs. $13.83 million consensus.
Aspreva Pharmaceuticals (Nasdaq: ASPV) 7% LOWER; reports Q1 EPS of $1.03, cents better than estimates.(0.87) Revenues were $59.3 million vs. $58.74 million consensus.
PeopleSupport (Nasdaq: PSPT) 7% LOWER; reports Q1 EPS of $0.16, 6 cents better than estimates.(0.10) Revenues were $33.6 million vs. $32.45 million consensus. Sees Q2 EPS of $0.01-$0.03 versus the consensus of $0.10. Sees Q2 revs of $31-$32 million versus the consensus of $33.72 million. Sees FY EPS of $0.27-$0.38 versus the consensus of $0.43. Sees FY07 revs of $133-$137 million versus the consensus of $140.2 million.
Symantec (Nasdaq: SYMC) 6% HIGHER; reports Q4 EPS of $0.24, 4 cents better than estimates.(0.20) Revenues were $1.36 billion vs. $1.27 billion consensus. Sees Q1 EPS of $0.18-$0.20, versus the consensus of $0.24. Sees FY08 EPS of $1.10-$1.15 versus the consensus of $1.09.
RealNetworks (Nasdaq: RNWK) 5.8% HIGHER; reports Q1 EPS of $0.22, 5 cents better than estimates.(0.17) Revenues were $129.5 million vs. $125.26 million consensus. Sees Q2 EPS of $0.04-$0.06, versus the consensus of $0.00. Sees FY EPS of $0.23-$0.25 versus the consensus of $0.22. Sees FY revs of $547-$563M versus the consensus of $550.4M.
SuperGen (Nasdaq: SUPG) 5.8% LOWER; reports Q1 loss of $0.06, versus the consensus of a $0.02 profit. Revenues were $4.4 million vs. $10.93 million consensus.
Blackboard (Nasdaq: BBBB) 5% HIGHER; reports Q1 EPS of $0.07, 2 cents better than estimates.(0.05) Revenues were $55.3 million vs. $53.6 million consensus. Sees Q2 EPS of $0.08-$0.10, versus the consensus of $0.07. Sees FY EPS of $0.35-$0.41 versus the consensus of $0.39.
TASER (Nasdaq: TASR) 4.8% HIGHER; Jim Cramer said if conversative candidate Sarkozy wins the French Presidential election he promised to put a TASER in every police car in France
YM BioSciences Inc. (AMEX: YMI) 20% HIGHER; announced top-line results from its randomized, placebo-controlled Phase IIb trial of AeroLEF in opioid naive patients with post-operative pain following orthopedic surgery. AeroLEF met the primary endpoint of the study, showing a statistically significant difference in SPRID4 from placebo (p=0.0194).
NVE Corp (Nasdaq: NVEC) 14% HIGHER; reports Q1 EPS of $0.33, 6 cents better than estimates.(0.27) Revenues were $4.57 million vs. $4.38 million consensus.
MINRAD International, Inc. (AMEX: BUF) 11% HIGHER; announced it has received approval from the FDA to market Sojourn inhalation anesthetic.
Sirenza Micro (Nasdaq: SMDI) 11% HIGHER; reports Q1 EPS of $0.12, 2 cents better than estimates.(0.10) Revenues were $39.1 million vs. $36.97 million consensus.
Axcelis Technologies (Nasdaq: ACLS) 10% LOWER; reports Q1 EPS of $0.03, 1 cent worse than estimates.(0.04) Revenues were $97.5 million vs. $97.04 million consensus. Sees Q2 EPS of $0.03-$0.07 versus the consensus of $0.09. Sees Q2 revs of $108-$118 million versus the consensus of $113.4 million.
JDS Uniphase (Nasdaq: JDSU) 9% LOWER; reports Q3 EPS of $0.06, 4 cents worse than estimates.(0.10) Revenues were $361.7 million vs. $346.54 million consensus. Sees Q4 revs of $325-$345M versus the consensus of $354.5M.
Smith Micro Software (Nasdaq: SMSI) 9% LOWER; reports Q1 EPS of $0.20, 3 cents better than estimates.(0.17) Revenues were $17.7 million vs. $17.52 million consensus
Andersons (Nasdaq: ANDE) 8% LOWER; reports Q1 earnings of $0.51 per share above the consensus of $0.33. Revenues came in at $409.1 million versus the consensus of $326.8 million. Sees FY07 EPS of $2.35-$2.60 versus the consensus of $2.71.
Maxwell Technologies (Nasdaq: MXWL) 8% LOWER; reports Q1 loss of $0.25, 1 cent worse than estimates.(-.24) Revenues were $12.6 million vs. $13.83 million consensus.
Aspreva Pharmaceuticals (Nasdaq: ASPV) 7% LOWER; reports Q1 EPS of $1.03, cents better than estimates.(0.87) Revenues were $59.3 million vs. $58.74 million consensus.
PeopleSupport (Nasdaq: PSPT) 7% LOWER; reports Q1 EPS of $0.16, 6 cents better than estimates.(0.10) Revenues were $33.6 million vs. $32.45 million consensus. Sees Q2 EPS of $0.01-$0.03 versus the consensus of $0.10. Sees Q2 revs of $31-$32 million versus the consensus of $33.72 million. Sees FY EPS of $0.27-$0.38 versus the consensus of $0.43. Sees FY07 revs of $133-$137 million versus the consensus of $140.2 million.
Symantec (Nasdaq: SYMC) 6% HIGHER; reports Q4 EPS of $0.24, 4 cents better than estimates.(0.20) Revenues were $1.36 billion vs. $1.27 billion consensus. Sees Q1 EPS of $0.18-$0.20, versus the consensus of $0.24. Sees FY08 EPS of $1.10-$1.15 versus the consensus of $1.09.
RealNetworks (Nasdaq: RNWK) 5.8% HIGHER; reports Q1 EPS of $0.22, 5 cents better than estimates.(0.17) Revenues were $129.5 million vs. $125.26 million consensus. Sees Q2 EPS of $0.04-$0.06, versus the consensus of $0.00. Sees FY EPS of $0.23-$0.25 versus the consensus of $0.22. Sees FY revs of $547-$563M versus the consensus of $550.4M.
SuperGen (Nasdaq: SUPG) 5.8% LOWER; reports Q1 loss of $0.06, versus the consensus of a $0.02 profit. Revenues were $4.4 million vs. $10.93 million consensus.
Blackboard (Nasdaq: BBBB) 5% HIGHER; reports Q1 EPS of $0.07, 2 cents better than estimates.(0.05) Revenues were $55.3 million vs. $53.6 million consensus. Sees Q2 EPS of $0.08-$0.10, versus the consensus of $0.07. Sees FY EPS of $0.35-$0.41 versus the consensus of $0.39.
TASER (Nasdaq: TASR) 4.8% HIGHER; Jim Cramer said if conversative candidate Sarkozy wins the French Presidential election he promised to put a TASER in every police car in France
The Average American Is Losing Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.
Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.
But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
